The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2021 | CAR-T and BiTEs – which targets belong in clinical practice?
T-cell directed immune therapies, including chimeric antigen receptor (CAR)-modified T-cells and bispecific T-cell engagers (BiTEs) have revolutionized the treatment of multiple myeloma, providing unmatched benefits to many patients. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Orthopedic Center, New York, NY, discusses the clinical utility of established CAR-T and BiTE targets, including BCMA, CD38, FcRH5, and GPRC5D. Prof. Morgan believes that all targets will have a place in clinical practice, with individual patient immune characteristics and resistance development likely to be important considerations for treatment sequencing. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
